| 摘要 |
The present invention relates to pharmaceutical formulations, in particular pharmaceutical formulations in which the active ingredient comprises human antibodies to human interleukin I beta (IL-1²), in particular ACZ885 antibody, pharmaceutical formulations which are stable and aggregate-free upon storage and delivery. |
